Study Finds Meds May Slow Alzheimer’s in New Way

Published on September 12, 2024

Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid…

Read Full Article (External Site)